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Regulatory role of hexosamine 
biosynthetic pathway on hepatic 
cancer stem cell marker CD133 
under low glucose conditions
Shu-Hai Lin1,*, Tengfei Liu1,*, Xiaoyan Ming2, Zhi Tang1, Li Fu3, Philippe Schmitt-Kopplin4, 
Basem Kanawati4, Xin-Yuan Guan2 & Zongwei Cai1
Cancer was hypothesized to be driven by cancer stem cells (CSCs), but the metabolic determinants of 
CSC-like phenotype still remain elusive. Here, we present that hexosamine biosynthetic pathway (HBP) 
at least in part rescues cancer cell fate with inactivation of glycolysis. Firstly, metabolomic analysis 
profiled cellular metabolome in CSCs of hepatocellular carcinoma using CD133 cell-surface marker. The 
metabolic signatures of CD133-positive subpopulation compared to CD133-negative cells highlighted 
HBP as one of the distinct metabolic pathways, prompting us to uncover the role of HBP in maintenance 
of CSC-like phenotype. To address this, CSC-like phenotypes and cell survival were investigated 
in cancer cells under low glucose conditions. As a result, HBP inhibitor azaserine reduced CD133-
positive subpopulation and CD133 expression under high glucose condition. Furthermore, treatment 
of N-Acetylglucosamine in part restores CD133-positive subpopulation when either 2.5 mM glucose 
in culture media or glycolytic inhibitor 2-deoxy-D-glucose in HCC cell lines was applied, enhancing 
CD133 expression as well as promoting cancer cell survival. Together, HBP might be a key metabolic 
determinant in the functions of hepatic CSC marker CD133.
Mounting evidence demonstrates that tumor is hierarchically organized and consists of heterogeneous popula-
tion of cells, in which a small subpopulation of cells named cancer stem cells (CSCs), has been best characterized 
by the features to initiate tumor growth, self-renew, and differentiate1. Up to date, CSCs have been found in a 
wide range of human cancers, including liver cancer2, breast cancer3, glioblastoma4, lung cancer5, and leukemia6.
CD133 was first identified as a primitive hematopoietic and progenitor cell’s marker and widely used alone or 
in combination with other stem cell markers to enrich stem cell from multiple tissues like brain, liver, pancreas 
and bone marrow7. It’s now widely used as a CSC marker to isolate CSCs from human liver tumors. It’s true and 
clear that CD133-positive, compared to the counterpart CD133-negative, endows with the features, the preferen-
tial capacities of cancer cell and stem cell, of increased ability to promote tumorigenicity and metastasis in vitro 
and in vivo, as well as the ability to differentiate into varied lineages. CD133-positive subset harbors the upregu-
lation of stem cell related genes, such as Bmi1, Notch, and beta-catenine. Moreover, CD133-positive subpopula-
tion cells also show the augment ability to form undifferentiated spheroids primarily as well as in vitro passages, 
meantime with upregulation of stem cell associated genes1. Aberrantly preferential upregulation of Akt and Bcl-2 
confers the CD133-positive subpopulation cells with survival characteristics, leading to chemoresistance and 
radioresistance8. Recently, Chai et al. reported that miR-142–3p regulates CSC-like properties in hepatocellu-
lar carcinoma (HCC) via the direct targeting of CD1339. More interestingly, the posttranslational modifications 
including phosphorylation and N-linked glycosylation of CD133 are also associated with CSC-like phenotypes 
and tumor growth10,11.
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Although the growing evidence elucidates some integral molecules and signaling pathways responsible for the 
stemness maintenance and differentiation of CD133-positive subpopulation cells12,13,14, the metabolic features of 
CD133-positive enriched CSCs and the effects of nutrients in CSCs remain inconclusive. Recently, energy metab-
olism in cancer cells has been highlighted in the tumor initiation and development and Warburg effect has been 
re-surveyed worldwidely15.
However, metabolic rewiring in CSCs has not been well characterized. To address this issue, it would be 
necessary to perform the emerging technique metabolomics for cellular metabolome. In this study, we isolated 
CD133-positive and counterpart CD133-negative subsets from human liver cancer cell line PLC8024 followed 
by metabolomics study based on Fourier transform ion cyclotron resonance mass spectrometry (FTICRMS) and 
ultrahigh-performance liquid chromatography quadrupole time-of-flight mass spectrometry (UPLC-QTOFMS) 
to profile the cellular metabolome. Uridine diphosphate-N-acetylglucosamine (UDP-GlcNAc), an end product 
in hexosamine biosynthetic pathway (HBP) was determined as the elevated level in CD133-positive subsets. This 
finding prompted us to ask whether HBP impacts CSC-like phenotype. Our data indicated that inhibition of HBP 
pathway by targeting the limiting-rate enzyme resulted in lowering the percentage of CD133-positive subpop-
ulations. Furthermore, N-acetylglucosamine (GlcNAc), which has been widely used to increase HBP product, 
could in part restore CD133-positive CSC phenotype and promote cell survival under low glucose conditions. 
Collectively, our investigation demonstrated that HBP might coordinate with glycolytic pathway for the regula-
tion of CD133 in hepatoma carcinoma cell lines.
Results
Metabolomics identifies hexosamine biosynthetic pathway in CD133-positive cancer 
cells. The CD133-positive subpopulation percentage of HCC cell lines have been examined and reported pre-
viously16. In our study, high resolution direct-infusion ion cyclotron resonance Fourier-transform mass spec-
trometry (DI-ICR-FT-MS) and ultrahigh performance liquid chromatography quadrupole time-of-flight mass 
spectrometry (UPLC-QTOFMS) were employed for untargeted metabolomics. The representative mass spectrum 
is shown in Figure S1. In the metabolomics workflow, peak picking followed by feature selection was performed 
by intensities of ions using XCMS package in R language. The metabolite identification was conducted by high 
mass accuracy and fragment ions as well as reference standards. As a result, a total of 32 differential metabolites 
were identified, covering glucose metabolism, amino acid metabolism, fatty acid and lipid metabolism (Table 1). 
Metabolite sets enrichment analysis (MSEA) was performed to highlight the metabolic difference between 
CD133-positive and CD133-negative subpopulations of PLC8024 cell line. Amino sugar metabolism, also known 
as hexosamine biosynthetic pathway (HBP), was identified to be most significant (Fig. 1A). Amino sugars are 
physiologically synthesized through the hexosamine biosynthetic pathway. In this pathway, the rate-limiting 
enzyme glutamine : fructose-6-phosphate-amidotransferase (GFPT) catalyzes fructose-6-phosphate to form glu-
cosamine-6-phosphate (GlcN6P) by consuming glutamine as an amino donor17. GlcN6P is rapidly converted 
to the end product UDP-GlcNAc which provides amino sugars for the biosynthesis of N- and O-linked protein 
glycosylation (Fig. 1B). In this regard, our metabolomic data raised a question whether HBP plays a key role for 
discriminating CD133-positive stemness phenotype in cancer cells.
Inhibition of HBP decrease the percentage of CD133-positive in HCC cell lines. Before verifying 
the role of HBP for maintaining the CSC-like phenotypes, we measured SOX2 and found higher expression in 
CD133-positive subpopulation compared to CD133-negative cells (Figure S2), indicating that CD133 is a good 
marker of stemness18. Therefore, we evaluated the next examination by using the marker CD133 and/or the per-
centage of CD133-positive cells. Firstly, we introduced an inhibitor of HBP, azaserine (AZA), which is widely used 
as a glutamine analog and the inhibitor of GFPT. We observed that the proportion of CD133-positive subpopula-
tion declined from 60.07% to 31.76% upon AZA treatment (Fig. 2A) and Western blotting assay also revealed that 
CD133 expression level negatively correlated with the dosage of AZA in PLC8024 cell line (Fig. 2B).
Glycolysis involved in the maintenance of CD133-positive subsets in HCC cell lines. Thus far, 
glucose has been well known to serve as one of the most important carbon sources and plays a critical role in 
highly proliferative cancer cells, although not all kinds of cancers. To examine the effect of glucose concentra-
tion on CSC-like phenotype, we further utilized low glucose condition (2.5 mM glucose in culture medium) for 
three HCC cell lines PLC8024, Huh7 and Hep3B containing CD133-positive subpopulation. The percentages 
of CD133-positive subset decreased significantly compared to the normal culture medium with high glucose 
(25 mM glucose) as the control: the percentage of CD133-positive subpopulation declined from around 60% to 
23.23% in PLC8024, and the percentages decreased from 63.27% to 47.65% and 66.60% to 50% in Hep3B and 
Huh7 cell lines, respectively (Fig. 3A).
Furthermore, we examined the gene expression pattern of the glycolytic pathway under low glucose condition 
by using the quantitative RT-PCR and observed a list of vital genes including GLUT2, PFKL, PGAM1, PKM2 
and LDHA (Fig. 3B,C) were consistently down-regulated significantly, suggesting that the glycolytic pathway 
might play a vital role for the maintenance of CSC-like phenotype. To confirm the CSC-like phenotype, the 
fluorescence-activation cell sorting (FACS) technique was used to isolate the CD133-positive subpopulation cells 
from PLC8024 and Western blotting was also performed to confirm subsequently that the expressions of PKM2 
and LDHA (Fig. 3D). These two enzymes at the last step of glycolytic pathway were also upregulated moder-
ately, hinting the glycolytic activation in CSCs of HCC cell line. To further validate the CSC-like phenotype 
is glycolytic pathway-dependent, we treated the cells with 2-DG, an inhibitor of glycolytic pathway. 2-DG is 
the glucose homologues and can be transported into the cells whereas could not be metabolized downstream, 
resulting in inhibition of glycolytic bioprocess. After 16h-administration of the HCC cell lines with 2-DG, the 
lactate secretion was significantly inhibited in PLC8024 and Hep3B cell lines (Fig. 4A). The flow-cytometry assay 
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displayed that the CD133-positive subpopulation cells was substantially reduced in PLC8024 (Fig. 4B). All the 
data suggested that glycolytic pathway played a critical role in regulating the CSCs enriched by CD133 in HCC 
cell line PLC8024, although only slight decrease of CD133-positive subpopulation in Hep3B and Huh7 cell lines 
was observed.
GlcNAc involved in the regulation of CD133-positive subset under glucose deprivation. For a 
better understanding of coordination of glycolysis and HBP in maintenance of CSC-like phenotype, we further 
examined the role of HBP pathway in the regulation of CD133-positive subpopulation. It’s well documented 
that GlcNAc could enter into the HBP and increase the production of UDP-GlcNAc, resulting in activation of 
HBP19. In light of this, we maintained the cell in presence of 10 mM GlcNAc overnight, after that, we treated the 
HCC cell lines with 50 μ g mL−1 Cycloheximide (CHX), an inhibitor of protein biosynthesis bioprocess. Western 
blotting indicated that the GlcNAc could elevate the protein stability (Fig. 5A). In addition, we found GlcNAc 
could restore the proportion of CD133-positive subpopulation under glucose deprivation partially but obviously, 
the proportion of CD133-positive subset was recovered to 37.38% after additional of 10 mM GlcNAc compared 
to 23.23% under 2.5 mM glucose conditional medium (Fig. 5B). Consistently, Western blotting also showed that 
GlcNAc could restore the CD133 protein expression under glucose deprivation conditional culture medium obvi-
ously (Fig. 5C). Intriguingly, optical microscope imaging demonstrated that the GlcNAc could maintain the cell 
growth, even under extremely low glucose condition or withdrawal of glucose completely (Fig. 6A,B). All of 
Metabolite raw mass (m/z) Possible assignments Fold-change P-value Postulated annotation
1 215.03281(i−)* glucose 1.96↑ 1.08E− 05
glucose and glutamine 
anaplerosis
2
147.0766(q + )
glutamine 2.04↑ 6.3E− 04
145.0600(q−)
3
148.0605(q + )
glutamate 1.46↑ 1.7E− 03
146.0439(q−)
4 175.1193(q + ) L-Arginine 1.65↑ 4.97E− 04 amino acid metabolism
5
306.07653(i−)
Glutathione 1.70 ↑ 3.74E− 05 low levels of reactive oxygen species308.0912
(q + )
306.0752(q−)
6 321.0509(q−) Thymidine monophosphate 2.65↑ 3.19E− 04 DNA synthesis
7 347.03988(i−) Inosine 5′-monophosphate 1.58 ↓ 1.27E− 02 nucleotide synthesis
8 498.28959(i−) Taurodeoxycholic acid Unique in CD133+ 1.72E− 03
bile acid transportation
9 516.3014(q+) Taurocholic acid 2.15↑ 6.47E− 05
10 440.24617(i+) Leukotriene E4 Unique in CD133+ 6.57E− 04
fatty acid biosynthesis
11 227.20167(i−) Myristic acid 1.49↑ 5.59E− 04
12 218.10340(i−) Pantothenic Acid 1.73↑ 1.31Eh03 Coenzyme-A synthesis
13 162.1107(q+) L-Carnitine 1.30↑ 1.22E− 04
fatty acid beta-oxidation
14 204.1231(q+) Acetylcarnitine 1.38↑ 1.44E− 03
15 300.04910(i−) N-Acetyl-D-glucosamine 6-phosphate/ N-Acetyl-D-glucosamine 1-phosphate 3.89↑ 5.0E− 02
hexosamine biosynthesis
16 606.07451(i−) Uridine diphosphate-N-acetylglucosamine 4.50↑ 1.2E− 04
17 399.14444(i+) S-Adenosyl-L-methionine 1.67↑ 8.10E− 03 hypermethylation
18 261.10833(i+) L-alpha-glutamyl-L-hydroxyproline 1.64↓ 3.31E− 03 Prolyl hydroxylase might be inhibited
19 132.0768(q+) Creatine 1.62↑ 7.31E− 04 helps to supply energy
20 245.04318(i−) Glycerophosphoglycerol 1.53↑ 0.002.67
Lipid accumulation 
suggests lipogenesis with 
tumorigenesis, metastasis 
and stemness.
21 258.1101(q+) Glycerophosphocholine 1.62↑ 1.88E− 03
22 425.26622(i+) 1-heptadecanoyl-glycero-3-phosphate 2.06 ↑ 8.79E− 04
23 518.3168(q+) LysoPC(18:3) 2.34↑ 5.35E− 05
24 520.3338(q+) LysoPC(18:2) 1.85↑ 4.15E− 05
25 524.3689(q+) LysoPC(18:0) 1.71↑ 4.64E− 05
26 548.3801(q+) LysoPC(20:2) 2.44↑ 1.19E− 04
27 648.3800(q+) 1-Palmitoyl-2-(5-keto-8-oxo-6-octenoyl)-sn-glycero-3-phosphatidylcholine 2.34↑ 6.59E− 05
28 650.3959(q+) 1-Palmitoyl-2-(5-hydroxy-8-oxo-6-octenoyl)-sn-glycero-3-phosphatidylcholine 2.38↑ 9.97E− 07
29 702.4985(q+) PC(18:2/12:0) 2.76↑ 4.065E− 05
30 764.5063(q+) PC(22:6/13:0) 1.74↑ 3.29E− 04
31 766.5308(q+) PC(20:5/15:0) 1.86↑ 8.61E− 04
32 780.5437(q+) PC(22:4/14:1) 1.76↑ 9.68E− 04
Table 1. The metabolites in PLC8024 were putatively identified (CD133-positive versus CD133-negative). 
(i+ ): FTICRMS-ESI (+ ); (i− ): FTICRMS-ESI (− ); (q+ ): QTOFMS-ESI (+ ); (q− ): QTOFMS-ESI (− ). *The 
mass was assigned to be [glucose+ Cl]−; LysoPC: lysophosphatidylcholine; PC: phosphatidylcholine.
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these data confirmed that the GlcNAc could support cell survival under glucose deprivation, maintaining the 
CSC-like phenotype. To validate our hypothesis and previous finding, we introduced the soft-agar assay, which 
is the in vitro experiment to evaluate the long term proliferation and self-renewal ability of CSCs. After isolation 
the CD133-positive subset and negative counterpart via FACS technique, we kept these cells in soft agar with the 
different glucose concentration from low to high, in presence of GlcNAc or not. After 3-week culture, we found 
that GlcNAc could promote the colony formation under low glucose concentration significantly (Fig. 6C).
Discussion
Metabolic reprogramming has been recognized as a hallmark in cancer cells15. In particular, Warburg effect has 
been hypothesized many decades ago to emphasize the role of glucose metabolism in tumorigenesis20,21. The 
branched pathways of glycolysis in cancer cells, however, are still ill defined. In this regard, it is necessary to apply 
a new approach for a broader investigation of metabolic pathways. Metabolomics as the downstream of systems 
Figure 1. Hexosamine biosynthetic pathway (HBP) was highlighted in cancer stem cells. (A) Metabolite 
sets enrichment analysis of the differential metabolites reveals that the highest impact of the pathways is amino 
sugar metabolism. (B) Schematic diagram of HBP. GFPT is the first rate-limiting enzyme in HBP, and N-acetyl-
glucosamine (GlcNAc) can enter into and activate the HBP. The proposed role of HBP in maintaining the cancer 
stem cell phenotype enriched by CD133 in hepatoma carcinoma cell lines for further investigations.
Figure 2. Hexsoamine biosynthetic pathway involved in the maintenance of CSC-like phenotype in 
PLC8024 cell line. (A) AZA treatment reduces the percentage of CD133 in PLC8024 parental cells.  
(B) Expression of CD133 was determined by western blotting. The PLC8024 was cultured in high glucose 
medium in presence of AZA with different concentrations (5, 10, 25, 50, 100 μ M ) or a vehicle control (DMEM 
only). Beta-actin was used as loading control.
www.nature.com/scientificreports/
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biology, by using an array of chromatographic techniques coupled with mass spectrometry, has been developed 
and applied in cellular metabolism. To characterize the metabolic signatures in CSCs, both DI-ICR-FT-MS and 
UPLC-QTOFMS were used in non-targeted metabolomics to obtain high-resolution snapshots of the metabolic 
state of a system, by providing highly accurate masses for metabolite identification.
Of note, HBP was identified to be one of important pathways for discrimination of CSCs and non-CSCs 
using CD133 as a marker in our study, suggesting that HBP may play a critical role in maintenance of stem 
cell-like phenotype. HBP diverts from F6P, requiring glutamine for incorporation of amino group in the down-
stream products. The critical role of HBP has been demonstrated to provide glycosylation of proteins including 
O-GlcNAcylation, promoting tumor cell growth under glucose deprivation22,23. In this work, we observed that 
inhibition of HBP leaded to down-regulation of CD133-enriched CSCs, suggesting that HBP involved in the 
maintenance of CSC-like phenotype within HCC cell line and corroborating our metabolic characterization.
In order to modulate the HBP activity, we further administrated the cells with GlcNAc. It’s well documented 
that GlcNAc can enter into the cell via cell bulk endocytosis and is phosphorylated by the salvage pathway enzyme 
N-acetylglucosamine kinase. GlcNAc is converted to the intermediate metabolite GlcN6P and consequently con-
tribute to the end production of the HBP, UDP-GlcNAc19,24. Our experiment data demonstrated that GlcNAc 
supplementation contributes to stabilize CD133 protein level, and promote cell survival. Recent published inves-
tigation demonstrate that CD133, beyond as a CSC marker, still functions involved in survival through regulation 
of autophagy and glucose uptake, which may be necessary for CSCs to survive in tumor microenvironment25,26. 
Whether HBP plays a role in maintaining CSC-like phenotype for cancer survival under glucose deprivation that 
common phenomenon observed in solid tumor, remain elusive and need to further study.
Inhibition of glycolytic pathway by 2-DG resulted in lower of CD133-positive phenotype. Unlike PLC8024 that 
with considerable downregulation, Huh7 and Hep3B cell lines showed not significant but reproducible decrease 
Figure 3. Glucose plays an important role in maintaining the cancer stem cell phenotype enriched by 
CD133 in hepatoma carcinoma cell lines. (A) The percentage of CD133-positive subsets was analyzed by flow 
cytometry. The green line represent the cell were maintained in high-glucose (25 mM) condition and red line 
indicate the cell were cultured in low glucose (2.5 mM) condition. (B) Schematic diagram of glycolytic pathway 
and involved genes. (C) Real-time PCR analysis of mRNA expression of GLUT1, GLUT2, PFKL, GAPDH, 
PGAM1, LDHA and PKM2 under high and low glucose conditions in PLC8024 cell line. (D) The key glycolytic 
enzymes (LDHA and PKM2) were determined by Western blotting. Beta-actin was used as loading control.
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of CD133-positive subpopulation (Figure S3). We suspected that CD133-enriched CSCs within PLC8024 may 
be more susceptible to glucose metabolism modulation. Consistently and as we expected, when Huh7 and 
Hep3B were exposed to 2-DG in the presence of GlcNAc, we could observe slight but reproducible restoration of 
CD133-positive subgroups.
Nevertheless, our study raised more interest in the role of metabolism in CSCs. Indeed, a new item “meta-
bostemness” was coined to describe the metabolic alterations in CSCs27. How metabolism impacts on stem 
cell-like phenotype shows potential interest and provides a new vista for cancer therapy28,29. Recently investi-
gation indicated that levels of enzymes and metabolites involved in glycolysis, the citric acid (TCA) cycle, and 
cysteine and methionine metabolism are altered in colorectal CSCs. The metabolic signature provides mecha-
nistic insights into colorectal CSCs phenotypes and may serve as potential biomarkers and therapeutic targets 
for future colorectal cancer treatment30. Our study showed significant description that HBP play a vital role in 
maintenance of CSCs’ phenotype within HCC, providing a new avenue for future CSCs-targeted cancer study.
Methods
Cell culture. PLC8024, Huh7 and Hep3B cell lines were obtained from the Institute of Virology, Chinese 
Academy of Medical Sciences (Beijing, China). All the cell lines were maintained in Dulbecco’s modified Eagle’s 
medium supplemented with 10% fetal bovine serum. All cells were cultured at 37 °C with an atmosphere of 5% 
CO2 and 95% air.
Metabolomic profiling. CD133-positive CSCs were obtained by cell sorting from PLC8024, fol-
lowing by metabolite extraction and mass spectrometry-based metabolomic analysis. Direct-infusion 
ion-cyclotron-resonance Fourier-transform spectrometry (DI-ICR-FT-MS) was used for measurement of the 
metabolites, and home-made matrix generator was performed for peak alignment31. Meanwhile, ultrahigh per-
formance liquid chromatography quadrupole time-of-flight mass spectrometry (UPLC-QTOFMS) was also 
employed combining with XCMS program in R language. Subsequently, the differentiating ions were introduced 
into the databases for metabolite identification, like massTRIX (www.masstrix.org) and Metlin (http://metlin.
scripps.edu). As a result, the compilation of differentiating metabolites was assigned to metabolic pathways for 
Figure 4. (A) Lactate was measured fluorometrically. Cells were seeded and serum starved 16 h followed by 
replaced with fresh medium in presence of 20 mM 2-DG or not. Lactate measured in cell culture supernatants 
showing quantity (μ mol) per 106 of tested cells. Samples were diluted 2–5 fold. (B) HCC cell lines were cultured 
under high glucose medium in presence of 20 mM 2-DG or vehicle control (DMEM only) for 16 h, and CD133-
positive phenotype were detected by flow-cytometry. Each experiment was repeated at least three times. 
Representative data are shown.
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discriminating CD133-positive cells from CD133-negative subpopulations. The details of metabolite extraction 
and mass spectrometric conditions and statistical analysis were described in supporting information.
Reagents and antibodies. Mouse IgG1 K Isotype Control PE was purchased from eBioscience (San Diego, 
CA); anti-CD133/1 (W6B3C1) mouse mAb and phycoerythrin (PE)-conjugated CD133/1(AC133-PE) anti-
body were obtained from miltenyi (Aubum, CA) were obtained from Cell Signaling Technology (Beverly, MA); 
glycolysis related antibodies including anti-PKM2 (D78A4) rabbit mAb and anti-LDHA (C4B5) rabbit mAb 
from Glycolysis Antibody Sampler Kit (#8337) were purchased from Cell Signaling Technology (Beverly, MA); 
anti-Beta-actin (ab6276) mouse mAb were from Abcam (Cambridge, UK); horseradish peroxidase-conjugated 
goat anti-mouse and goat anti-rabbit were from Sigma – Aldrich (St. Louis, MO). Chemicals including 
2-Deoxy-D-glucose (2DG), N-Acetylglucosamine (GlcNAc), Azaserine and Dulbecco′ s Modified Eagle′ s 
Medium powder (D5030) were purchased from Sigma–Aldrich (St. Louis, MO).
Fluorescence-activated cell sorting. (PE)-conjugated CD133/1(AC133-PE) antibody was used for 
cell staining according to the manufacture’s protocol. Briefly, 1 × 107 cells were determined and washed with 
sterile PBS twice. Resuspended cells in 80 μ L buffer (PBS with 2% fetal bovine serum), additional of 20 μ L FcR 
Blocking reagent followed with 10 μ L CD133/1(AC133) antibody. Mixed gently and incubated at 4°C in the dark 
for 30 min. After washing for 3 times with PBS, cells were sorted and analyzed on a BD FACSVantage SE (BD 
Biosciences). Isotype matched mouse IgG used for negative control.
Western blotting analysis. Cells were lysated in a RIPA buffer (50 mM Tris pH = 7.6, 1% Triton, 150 mM 
NaCl, 2 mM EDTA, protein inhibitor mixture(Roche), 1 mM NaF, 1 mM Na3VO4). Equal amounts of proteins 
were separated by 10% or 12% SDS-PAGE followed by transferred to PVDF membrane. The membranes were 
blocked in 5% non-fat milk for 1 h at room temperature and incubated with primary antibody overnight at 4 °C. 
After washing 3 times the second day, the blots were incubated with HRP-conjugated anti-mouse or anti-rabbit 
secondary antibodies at room temperature for 1 h. The antibody signal will be visualized using an enhanced 
chemiluminescence system (Pierce Biotechnology).
RNA isolation, reverse transcription and qRT-PCR. Cells were collected and washed with PBS twice, 
total RNA was extracted using Trizol Reagent (Takara Bio, Japan) and cDNA were synthesized using Prime 
ScriptTM RT Master Mix (Takara, Japan) according to the manufacturers’ instructions, respectively. The quan-
titative Real-time PCR was carried out using FastStart Universal SYBR Green Master (Roche, Germany) and 
ABI PRISM 7900 Sequence Detector (Applied Biosystems, Foster City, CA). The cycling parameters were 95 °C 
for 30 min, 55 °C for 1 min, and 72 °C for 2 min for 40 cycles, followed by a melting curve analysis. The threshold 
cycle (CT) was measured during the exponential amplification phase, and the amplification plots were analyzed 
Figure 5. The supplementation of GlcNAc plays an important role in maintenance of cancer stem cell-
like phenotype. (A) PLC8024 and Huh7 cell lines were pre-treated with 10 mM GlcNAc or the vehicle control 
(DMEM only) for 12 h. After that, cells were treated with CHX (50 μ g mL−1) or the vehicle control (DMSO) 
for indicated time. The expression of CD133 was examined by Western blotting and Beta-actin was used as 
loading control. (B) The PLC8024 cell line was cultured in high glucose, low glucose or low glucose in presence 
of 10 mM GlcNAc for 48 h and CD133-positive subpopulation was determined by flow cytometry. (C) The 
PLC8024 cells were cultured in high glucose, low glucose or low glucose in presence of 10 mM GlcNAc for 48 h 
and expression of CD133 was examined by Western blotting and Beta-actin was used as loading control.
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through SDS 1.9.1 software (Applied Biosystems, Foster, City, CA). The primers used for qRT-PCR listed in sup-
plementary Table S1.
Anchorage-independent growth Assay. Cells were trypsined and washed with PBS twice and were sus-
pended in 0.3% soft agar dissolved with culture medium in 6-well plates at a density of 6000 cells per well. After 
3 weeks, anchorage-independent colonies (≥ 50 cells) were counted under optical microscope in random 8 fields 
per well and photographed.
Lactate production determination assay. Lactate production was measured using a lactate assay kit 
(BioVision) according to the manufacturer’s instructions as described otherwise32.
Statistical analysis and metabolic annotation. Metabolomic data analysis followed our previous pub-
lications33,34. Briefly, the DI-ICR-FT-MS mass spectra were exported to peak lists for alignment. After performing 
this data filtration by 80% rule, two-tailed student’s t-test was used for calculation of P-value. In addition, the 
differential ions were implemented into MassTRIX interface (http://www.masstrix.org) to search for differentiat-
ing metabolites. The criteria in database searching were as follows: negative ionization (correct for H+ loss) was 
selected as scan mode; maximum error was up to 1.0 ppm. The acquired data from UPLC-QTOFMS were pro-
cessed using XCMS package for a matrix containing arbitrarily assigned peak index (retention time-m/z pairs), 
sample names (observations) and ion intensity information (variables). Differential metabolites were interfaced 
with a web-based tool (http://www.metaboanalyst.ca/) for the pathway analysis and visualization. The Wilcoxon 
Mann− Whitney test was performed for the biochemical and metabolomic data, and P < 0.05 was considered as 
significant.
References
1. Ma, S. et al. Identification and characterization of tumorigenic liver cancer stem/progenitor cells. Gastroenterology 132, 2542–2556 
(2007).
2. Suetsugu, A. et al. Characterization of CD133 + hepatocellular carcinoma cells as cancer stem/progenitor cells. Biochem Biophys Res 
Commun 351, 820–824 (2006).
Figure 6. The supplementation of GlcNAc plays an important role in cancer cell survival under low 
glucose condition. (A) PLC8024 cells were seeded in 6-well plate and maintained in conditional medium with 
indicated glucose concentration (25 mM, 2.5 mM, 0.75 mM and 0 mM) in presence of 10 mM GlcNAc or the 
vehicle control (DMEM only) for 48 h. The representative images were captured by bright field microscope. (B) 
The histogram represents quantitative analysis of the mean values of survival cells in triplicate determinations. 
Asterisk indicates the significant difference. *P ﹤ 0.05. (C) The conditional soft agar assay medium with different 
glucose concentration (25 mM, 10 mM, 5 mM, 2.5 mM) were pre-prepared. The CD133-positive subpopulation 
cells and CD133-negative counterpart isolated from PLC8024 were maintained in conditional soft agar assay 
medium with additional of 10 mM GlcNAc or the vehicle control (DMEM only) for 3 weeks. The representative 
images were captured by bright field microscope. All pictures were all at same magnification, resolution and 
size. The histogram represents the quantitative analysis of mean values of colony formation in conditional soft 
agar assay medium in triplicate determinations. Asterisk indicates the significant difference. *P ﹤ 0.05.
www.nature.com/scientificreports/
9Scientific RepoRts | 6:21184 | DOI: 10.1038/srep21184
3. Al-Hajj, M., Wicha, M.S., Benito-Hernandez, A., Morrison, S.J. & Clarke, M.F. Prospective identification of tumorigenic breast 
cancer cells. Proc Natl Acad Sci USA 100, 3983–3988 (2003).
4. Singh, S.K. et al. Identification of human brain tumour initiating cells. Nature 432, 396–401 (2004).
5. Kim, C.F. et al. Identification of bronchioalveolar stem cells in normal lung and lung cancer. Cell 121, 823–835 (2005).
6. Bonnet, D. & Dick, J.E. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic 
cell. Nat Med 3, 730–737 (1997).
7. Yin, A.H. et al. AC133, a novel marker for human hematopoietic stem and progenitor cells. Blood 90, 5002–5012 (1997).
8. Ma, S., Lee, T.K., Zheng, B.J., Chan, K.W. & Guan, X.Y. CD133 + HCC cancer stem cells confer chemoresistance by preferential 
expression of the Akt/PKB survival pathway. Oncogene 27, 1749–1758 (2008).
9. Chai, S. et al. Regulatory role of miR-142-3p on the functional hepatic cancer stem cell marker CD133. Oncotarget 5, 5725–5735 
(2014).
10. Wei, Y. et al. Activation of PI3K/Akt pathway by CD133-p85 interaction promotes tumorigenic capacity of glioma stem cells. Proc 
Natl Acad Sci USA 110, 6829–6834 (2013).
11. Liu, Y. et al. Mutation of N-linked glycosylation at Asn548 in CD133 decreases its ability to promote hepatoma cell growth. 
Oncotarget 6, 20650–20660 (2015).
12. Sakurai, T., Maeda, S., Chang, L. & Karin, M. Loss of hepatic NF-kappa B activity enhances chemical hepatocarcinogenesis through 
sustained c-Jun N-terminal kinase 1 activation. Proc Natl Acad Sci USA 103, 10544–10551 (2006).
13. Yang, Z. et al. Transient mTOR inhibition facilitates continuous growth of liver tumors by modulating the maintenance of 
CD133 + cell populations. PLoS One 6, e28405 (2011).
14. Zhang, L. et al. BMP4 administration induces differentiation of CD133 + hepatic cancer stem cells, blocking their contributions to 
hepatocellular carcinoma. Cancer Res 72, 4276–4285 (2012).
15. Hanahan, D. & Weinberg, R.A. Hallmarks of cancer: the next generation. Cell 144, 646–674 (2011).
16. Ma, S. et al. Aldehyde dehydrogenase discriminates the CD133 liver cancer stem cell populations. Mol Cancer Res 6, 1146–1153 
(2008).
17. Marshall, S., Bacote, V. & Traxinger, R.R. Discovery of a metabolic pathway mediating glucose-induced desensitization of the 
glucose transport system. Role of hexosamine biosynthesis in the induction of insulin resistance. J Biol Chem 266, 4706–4712 
(1991).
18. Kyjacova, L. et al. Radiotherapy-induced plasticity of prostate cancer mobilizes stem-like non-adherent, Erk signaling-dependent 
cells. Cell Death Differ 22, 898–911 (2015).
19. Wellen, K.E. et al. The hexosamine biosynthetic pathway couples growth factor-induced glutamine uptake to glucose metabolism. 
Genes Dev 24, 2784–2799 (2010).
20. Warburg, O. On the origin of cancer cells. Science 123, 309–314 (1956).
21. Vander, Heiden, M.G., Cantley, L.C. & Thompson, C.B. Understanding the Warburg effect: the metabolic requirements of cell 
proliferation. Science 324, 1029–1033 (2009).
22. Jones, D.R. et al. The hexosamine biosynthesis pathway and O-GlcNAcylation maintain insulin-stimulated PI3K-PKB 
phosphorylation and tumour cell growth after short-term glucose deprivation. FEBS J 281, 3591–3608 (2014).
23. Kang, J.G. et al. O-GlcNAc protein modification in cancer cells increases in response to glucose deprivation through glycogen 
degradation. J Biol Chem 284, 34777–34784 (2009).
24. Lau, K.S. & Dennis, J.W. N-Glycans in cancer progression. Glycobiology 18, 750–760 (2008).
25. Chen, H. et al. CD133/prominin-1-mediated autophagy and glucose uptake beneficial for hepatoma cell survival. PLoS One 8, 
e56878 (2013).
26. Chen, H. et al. Low glucose promotes CD133mAb-elicited cell death via inhibition of autophagy in hepatocarcinoma cells. Cancer 
Lett 336, 204–212 (2013).
27. Menendez, J.A. & Alarcon, T. Metabostemness: a new cancer hallmark. Front Oncol 4, 262 (2014).
28. Singh, S.R., Tan, M. & Rameshwar, P. Cancer metabolism: targeting metabolic pathways in cancer therapy. Cancer Lett 356, 147–148 
(2015).
29. Boroughs, L.K. & DeBerardinis, R.J. Metabolic pathways promoting cancer cell survival and growth. Nat Cell Biol 17, 351–359 
(2015).
30. Chen, K.Y. et al. A metabolic signature of colon cancer initiating cells. Conf Proc IEEE Eng Med Biol Soc 2014, 4759–4762 (2014).
31. Witting, M. et al. DI-ICR-FT-MS-based high-throughput deep metabotyping: a case study of the Caenorhabditis elegans-
Pseudomonas aeruginosa infection model. Anal Bioanal Chem 407, 1059–1073 (2015).
32. Vlashi, E. et al. Metabolic state of glioma stem cells and nontumorigenic cells. Proc Natl Acad Sci USA 108, 16062–16067 (2011).
33. Lin, S. et al. Hippocampal metabolomics using ultrahigh-resolution mass spectrometry reveals neuroinflammation from 
Alzheimer’s disease in CRND8 mice. Anal Bioanal Chem 405, 5105–5117 (2013).
34. Lin, S. et al. Ultrahigh resolution mass spectrometry-based metabolic characterization reveals cerebellum as a disturbed region in 
two animal models. Talanta 118, 45–53 (2014).
Acknowledgements
The authors would like to thank Dr. Kwan Ho Tang for his assistance in cell sorting. This work was supported 
by Hong Kong Research Grant Council Collaborative Research Fund (HKBU5/CRF/10) to Z.C. Faculty 
Research Grant of Hong Kong Baptist University (FRG2/13-14/051) to S.-H.L. and the National Natural Science 
Foundation of China (NSFC-21377106) to S.-H.L.
Author Contributions
S.-H.L., T.L., X.-Y.G. and Z.C. designed the experiments and wrote the manuscript. S.-H.L. and T.L. performed 
the experiments and analyzed the data. X.M., Z.T. and L.F. helped to perform cell biology and mass spectrometric 
experiments as well as data analysis. P.S.-K. and B.K. provided the instruments and helped to perform the 
metabolomics analysis. All authors reviewed the manuscript.
Additional Information
Supplementary information accompanies this paper at http://www.nature.com/srep
Competing financial interests: The authors declare no competing financial interests.
How to cite this article: Lin, S.-H. et al. Regulatory role of hexosamine biosynthetic pathway on hepatic cancer 
stem cell marker CD133 under low glucose conditions. Sci. Rep. 6, 21184; doi: 10.1038/srep21184 (2016).
www.nature.com/scientificreports/
1 0Scientific RepoRts | 6:21184 | DOI: 10.1038/srep21184
This work is licensed under a Creative Commons Attribution 4.0 International License. The images 
or other third party material in this article are included in the article’s Creative Commons license, 
unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, 
users will need to obtain permission from the license holder to reproduce the material. To view a copy of this 
license, visit http://creativecommons.org/licenses/by/4.0/
